Companion Diagnostic Studies. Studies reasonably anticipated to show that current drugs, not commonly used, can be better selected and efficacious for patients using Galectin-3 levels. Studies reasonably anticipated to show that Galectin-3 may be useful in identifying heart failure patients for new drugs.
Appears in 5 contracts
Samples: Galectin 3 License and Distribution Agreement (BG Medicine, Inc.), Galectin 3 License and Distribution Agreement (BG Medicine, Inc.), Galectin 3 License and Distribution Agreement (BG Medicine, Inc.)
